Positron emission tomography for nine cancers (bladder, brain, cervical, kidney, ovarian, pancreatic, prostate, small cell lung, testicular)
OBJECTIVE: To review and synthesize the evidence on the use of 18FDG-PET in the assessment and treatment of nine types of cancer with respect to the following clinical situations: diagnosis, staging, restaging, and monitoring response to treatment. DATA SOURCES: Comprehensive searches were conducted...
| Main Author: | |
|---|---|
| Corporate Authors: | , |
| Format: | eBook |
| Language: | English |
| Published: |
Rockville, MD
Agency for Healthcare Research and Quality
2008, 2008
|
| Series: | Technology assessment report
|
| Subjects: | |
| Online Access: | |
| Collection: | National Center for Biotechnology Information - Collection details see MPG.ReNa |
| Summary: | OBJECTIVE: To review and synthesize the evidence on the use of 18FDG-PET in the assessment and treatment of nine types of cancer with respect to the following clinical situations: diagnosis, staging, restaging, and monitoring response to treatment. DATA SOURCES: Comprehensive searches were conducted in four relevant electronic databases for the time period from 2003 to March 2008. REVIEW METHODS: Studies should be published in English, with more than 12 adult participants with primary cancer of the following type: bladder, brain, cervical, kidney, ovarian, pancreatic, prostate, small cell lung, and testicular. Restrictions regarding study design were not imposed. Two independent reviewers assessed study relevance, extracted the data and assessed the methodological quality of the studies. A combination of qualitative and quantitative approaches was used to synthesize the data. RESULTS: One hundred and nine articles were included in this report. The strongest evidence for the diagnostic accuracy of 18FDG-PET or 18FDG-PET/CT has been produced for staging of locally advanced cervical cancer and the detection and restaging of recurrent disease, the detection of ovarian cancer recurrences following treatment, and the diagnosing and initial staging of pancreatic cancer. These and other indications require further research to show the impact of 18FDG-PET or 18FDG-PET/CT on patient management or added value in the diagnostic and therapeutic process. CONCLUSION: For some type of cancers (e.g., cervical, ovarian, and pancreatic cancer), there is some evidence of the utility of 18FDG-PET or 18FDG-PET/CT for diagnosing, staging, or detecting recurrences, but they may still require more studies to augment the evidence base. Further studies are needed to reach firm conclusions about the clinical effectiveness of 18FDG-PET and 18FDG-PET/CT in terms of the impact on diagnosis and treatment options, patient-centered outcomes, and economic costs. It is still unclear how 18FDG-PET and 18FDG-PET/CT affects patient treatment and ultimately their outcome. For other types of cancer examined in the review (e.g., bladder, kidney, prostate, SCLC, and testicular) the answers are still inconclusive and require more careful study |
|---|---|
| Item Description: | Title from PDF t.p. - "This publication is provided for historical reference only and the information may be out of date.". - "December 1, 2008.". - "Project ID: PETC1207." |
| Physical Description: | 1 PDF file (xi, 175, J1 pages) illustrations |